미세 유두 갑상선암의 크기에 따른 임상상 및 단기간 치료 결과

Clinical Behaviors and Treatment Outcome of Papillary Thyroid Microcarcinomas:Tumor Size-Based Therapeutic Concept

  • 이잔디 (아주대학교 의과대학 외과학교실) ;
  • 오동규 (아주대학교 의과대학 외과학교실) ;
  • 임승수 (아주대학교 의과대학 외과학교실) ;
  • 남기현 (연세대학교 의과대학 외과학교실) ;
  • 정웅윤 (연세대학교 의과대학 외과학교실) ;
  • 소의영 (아주대학교 의과대학 외과학교실) ;
  • 박정수 (연세대학교 의과대학 외과학교실)
  • Lee, Jan-Dee (Department of Surgery, Ajou University College of Medicine) ;
  • Oh, Dong-Kyu (Department of Surgery, Ajou University College of Medicine) ;
  • Lim, Seung-Soo (Department of Surgery, Ajou University College of Medicine) ;
  • Nam, Kee-Hyun (Department of Surgery, Yonsei University College of Medicine) ;
  • Chung, Woong-Youn (Department of Surgery, Yonsei University College of Medicine) ;
  • Soh, Euy-Yong (Department of Surgery, Ajou University College of Medicine) ;
  • Park, Cheong-Soo (Department of Surgery, Yonsei University College of Medicine)
  • 발행 : 2008.05.31

초록

Purpose:The incidence of papillary thyroid microcarcinoma(PTMC) has increased due to the widespread use of high resolution ultrasonography and fine-needle aspiration biopsy. However, the clinical and biologic behaviors of PTMC is debatable. The aim of this study was to describe clinicopathologic features of PTMC and to suggest whether tumor size(5mm) might prove the useful parameter for determining the surgical strategy in PTMC. Material and Methods:From Jan. 2000 to Dec. 2005, 1355 of 2678 patients with papillary thyroid carcinoma were identified as having PTMC, based on tumor size${\leq}$10mm(50.6%). Among patients with PTMC, we further separated tumors<5mm(minute group:group M) from those 5 to 10mm(tiny group:group T). We compared the clinicopathological characteristics and the TNM stagings between two groups. Results:There were 114(8.4%) men and 1241(91.6%) women with a median age of 47 years(range;13-79). During a mean follow-up of 47.3(range;22-93), 13 patients(1.0%) developed locoregional recurrences and 3 patients(0.2%) showed distant metastases at initial presentation. Statistical analysis revealed that the presence of extracapsular invasion(p<0.0001), invasion to adjacent structure(p<0.0001), multifocality(p<0.0001), central lymph node metastasis(p<0.0001), and lateral lymph node metastasis(p<0.0001) were all significantly higher in tiny group(tumor${\geq}$5mm). Furthermore, minute group demonstrated a significantly lower tumor stage(AJCC TNM classification) compared with tiny group(p<0.0001). Conclusion:Patients with PTMC have a favorable treatment outcomes, although the distinction needs to be made with reference to the clinicopathologic behaviors. It would be reasonable to consider that tumor size(5mm) would be useful parameter for the treatment strategy of PTMC.

키워드

참고문헌

  1. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics 2004. Cancer J Clin. 2004;54:8-29 https://doi.org/10.3322/canjclin.54.1.8
  2. Pearce EN, Braverman LE: Papillary thyroid microcarcinoma outcomes and implications for treatment. J Clin Endocrinol Metab. 2004;89:3710-3712 https://doi.org/10.1210/jc.2004-1189
  3. Mazzaferri EL, Jhiang SM: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418-428 https://doi.org/10.1016/0002-9343(94)90321-2
  4. Falvo L, D'Ercole C, Sorrenti S, et al: Papillary microcarcinoma of the thyroid gland: Analysis of prognostic factors including histological subtype. Eur J Surg Oncol. 2003;588:28-32
  5. Wada N, Duh QY, Sugino K, et al: Lymph node metastasis from 259 papillary thyroid microcarcinoma: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg. 2003;237:399-407 https://doi.org/10.1097/00000658-200303000-00015
  6. Ito Y, Uruno T, Nakano K, et al: An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid. 2003;13:381-387 https://doi.org/10.1089/105072503321669875
  7. Harach HR, Franssila KO, Wasenius VM: Occult papillary carcinoma of the thyroid: A "normal"finding in Finland. A systemic autopsy study. Cancer. 1985;56:531-538 https://doi.org/10.1002/1097-0142(19850801)56:3<531::AID-CNCR2820560321>3.0.CO;2-3
  8. Hay ID, Grant CS, van Heerden JA, Goellner JR, Ebersold JR, Bergstralh EJ: Papillary thyroid microcarcinoma: A study of 535 cases observed in a 50-year period. Surgery. 1992;112:1139-1146
  9. Yamashita H, Noguchi S, Murakami N, et al: Extracapsular invasion of lymph node metastasis. A good indicator of disease recurrence and poor prognosis in patients with thyroid microcarcinoma. Cancer. 1999;86;842-849 https://doi.org/10.1002/(SICI)1097-0142(19990901)86:5<842::AID-CNCR21>3.0.CO;2-X
  10. Sugitani I, Fujimoto Y: Symptomatic versus asymptomatic papillary thyroid microcarcinoma: A retrospective analysis of surgical outcome and prognostic factors. Endocr J. 1999;46:209-216 https://doi.org/10.1507/endocrj.46.209
  11. Chow SM, Low SC, Chan JK, Au SK, Yau S, Lau WH: Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer. 2003;98:31-40 https://doi.org/10.1002/cncr.11442
  12. Burguera B, Gharib H: Thryoid incidentalomas. Prevalence, diagnosis, significance, and management. Endocrinol Metab Clin North Am. 2000;29:187-203 https://doi.org/10.1016/S0889-8529(05)70123-7
  13. Lo CY, Chan WF, Lang BH, Lam KY, Wan KY: Papillary microcarcinoma: Is there any difference between clinically overt and occult tumors? World J Surg. 2006;30:759-766 https://doi.org/10.1007/s00268-005-0363-8
  14. Pelizzo MR, Boschin IM, Toniato A, et al: Papillary thyroid microcarcinoma(PTMC): Prognostic factors, management and outcome in 403 patients. Eur J Surg Oncol 2006;32:1144-1148 https://doi.org/10.1016/j.ejso.2006.07.001
  15. Miccoli P, Minuto MN, Ugolini C, et al: Intrathyroidal differentiated thyroid carcinoma: Tumor size-based surgical concepts. World J Surg. 2007;31:888-894 https://doi.org/10.1007/s00268-006-0795-9
  16. Roti E, Rossi R, Trasforini G, et al: Clinical and histological characteristics of papillary thyroid microcarcinoma: Results of a retrospective study in 243 patients. J Clin Endocrinol Metab. 2006;91:2171-2178 https://doi.org/10.1210/jc.2005-2372
  17. Shah JP, Kian K, Forastiere A, Garden A, et al: American Joint Committee on Cancer. Cancer staging manual, 6th ed. New York: Springer-Verlag, 2002:77-87